Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer

Waters, 1999, Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial, Br J Cancer, 80, 269, 10.1038/sj.bjc.6690350 Vanhoefer, 2000, J Clin Oncol, 18, 2648, 10.1200/JCO.2000.18.14.2648 Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429 Kang, 2009, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 20, 666, 10.1093/annonc/mdn717 Al-Batran, 2008, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 26, 1435, 10.1200/JCO.2007.13.9378 Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149 Shirasaka, 2009, Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas, Jpn J Clin Oncol, 39, 2, 10.1093/jjco/hyn127 Boku, 2009, Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study, Lancet Oncol, 10, 1063, 10.1016/S1470-2045(09)70259-1 Koizumi, 2008, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial, Lancet Oncol, 9, 215, 10.1016/S1470-2045(08)70035-4 Ajani, 2010, Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial, J Clin Oncol, 28, 1547, 10.1200/JCO.2009.25.4706 Ajani, 2013, Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study, Eur J Cancer, 49, 3616, 10.1016/j.ejca.2013.07.003 Koizumi, 2010, Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study), Ann Oncol, 21, 1001, 10.1093/annonc/mdp464 Pocock, 1975, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, 31, 103, 10.2307/2529712 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Comets, 2003, Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients, J Pharmacokinet Pharmacodyn, 30, 257, 10.1023/A:1026142601822 Chuah, 2011, Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients, Cancer Sci, 102, 478, 10.1111/j.1349-7006.2010.01793.x